PE 22-28 is a new generation short neuropeptide developed based on the natural regulatory mechanisms of the brain. It is an active fragment of the peptide system involved in mood control, neurogenesis, and stress adaptation. In studies, PE 22-28 showed a pronounced potential in gently normalizing the emotional background and supporting cognitive functions through targeted effects on neuronal ion channels.
PE 22-28 is considered as a neuropeptide bioregulator that supports the health of the nervous system and contributes to the preservation of cognitive and emotional resources with age. This makes it an important element of longevity approaches focused on the brain and the psycho-emotional state.
General information
| Features | Values |
|---|---|
| The peptide sequence | Gly-Val-Ser-Trp-Gly-Leu-Arg |
| The molecular formula | C35H55N11O9 |
| Molecular weight | 773.89 g/mol |
| CAS Number | 1801959-12-5 |
| PubChem CID | 165437303 |
| Synonyms | PE-22-28, PE 22-28 |
Lyophilized peptides
All peptides undergo lyophilization, a process that is necessary to extend their shelf life, as well as preserve the purity and integrity of the peptides during storage and transportation. Product Usage: This product is intended solely for research purposes. All product information provided on this website is intended for educational purposes.
Product Usage
This product is intended solely for research purposes. All product information provided on this website is intended for educational purposes.
The purity of peptides is more than 99%
Confirmed by certified laboratories. The analysis certificates are available before purchase.
GMR Production Standards
Manufactured in enterprises in accordance with good manufacturing practices. Complete documentation on tracking the origin of the product.
Execution of orders at the highest level
Sending orders the next day at checkout before 12:00 Moscow time. Free standard shipping across the country for orders starting from 15,000₽ (or equivalent).
Without fillers and additives
Only pure active connections. The composition is confirmed by experts for reliable in vitro studies.
PE 22-28 is a short synthetic peptide developed on the basis of spadin and considered as a promising research inhibitor of the TREK-1 potassium channel. In reviews on TREK-1, it is described as a 7-amino acid shortened analog, which showed higher affinity for TREK-1 and better in vivo stability compared to spadin. The main interest in PE 22-28 is related to studies of depression, neurogenesis, synaptogenesis, and regulation of neuronal excitability. Today, his data remains mostly preclinical. Role of TREK-1 in Health and Disease, Focus on the Central Nervous System - PMC
Antidepressant treatment
The main area of study of PE 22-28 is related to the rapid antidepressant response model through TREK-1 blockade. In the work of Djillani et al. PE 22-28 reduced the immobilization time in the forced swim test and reduced the latency of food intake in the novelty suppressed feeding test after a short course, which supported interest in it as a fast-acting spadino-like peptide. In reviews on TREK-1, this mechanism is considered as a separate research strategy, different from classical monoaminergic antidepressants. Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity - PubMed
TREK-1 blockade and mechanism of action
PE 22-28 is studied primarily as a high-affinity blocker of TREK-1, a two-pore potassium channel KCNK2 involved in the regulation of mood, neuronal activity, and stress response. In the full text of the 2017 paper, an IC50 of about 0.12 nM is indicated for PE 22-28, whereas for spadin it was significantly higher, about 40 nM. Additionally, the authors showed that PE 22-28 had no significant effect on TREK-2, TRAAK, TRESK, and TASK-1 in the models used, which supports its relative selectivity specifically to TREK-1. Shortened Spadin Analogues Display Better TREK-1 Inhibition, In Vivo Stability, and Antidepressant Activity - PMC
Neurogenesis and synaptogenesis
A separate interest in PE 22-28 is related to its effect on the plasticity of nervous tissue. In preclinical experiments, a short course of PE 22-28 and its analogues was accompanied by increased neurogenesis in the hippocampus, and an increase in PSD-95 levels was observed in the culture of cortical neurons, which was interpreted as increased synaptogenesis. This is what makes the peptide interesting not only for models of depressive behavior, but also for studies of neuronal remodeling. Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity - PubMed
Stability and advantages over spadin
PE 22-28 was identified as the most successful shortened fragment of spadin after analysis of its degradation products and screening of shorter sequences. The authors showed that PE 22-28 proved to be the most effective short-term TREK-1 inhibitor among the tested variants, and further analogues based on it were created to further improve stability and duration of action. The reviews also note that shortening to PE 22-28 made it possible to obtain the shortest active antidepressant fragment in this line of molecules. Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity - PMC
Links